Eli Lilly released positive topline results from the Phase IIIb TOGETHER-PsA study. The trial combined the arthritis drug Taltz (ixekizumab) with the weight-loss drug Zepbound (tirzepatide). The combination therapy delivered significantly better outcomes for patients with psoriatic arthritis (PsA) and obesity than Taltz monotherapy.
The study successfully met its primary endpoint. At 36 weeks, 31.7% of patients receiving the combination therapy achieved the target outcome. This outcome required at least a 50% improvement in PsA activity and a 10% reduction in body weight.
Only 0.8% of patients on Taltz monotherapy achieved the same dual endpoint. Lilly noted these results could establish a new treatment paradigm that integrates weight management with inflammatory disease control for this patient population.